Literature DB >> 17674171

Transforming growth factor and nuclear factor kappa B mediated prophylactic cardioprotection by total flavonoids of fructus chorspondiatis in myocardial ischemia.

Jienan Ao1, Huijuan Feng, Fang Xia.   

Abstract

BACKGROUND: Chorspomias axillaries Batt et Hill, a well-known Chinese herb, has been used in clinical treatment of angina pectoris for hundreds of years, but its effective components and intrinsic cardioprotective mechanism are still beyond us. OBJECTIVES AND METHODS: In this study, we extracted Total Flavonoids of Fructus Chorspondiatis (TFFC), a potential effective component from Chorspomias axillaries Batt et Hill to investigate its effect on myocardial ischemia induced by isoproteronol in rat and elucidated its probable mechanism.
RESULTS: The results showed that prophylactically ;;intragastrical administration of TFFC at the dose of 200 mg/kg body weight effectively suppressed the variation of J points in electrocardiogram (0.211 +/- 0.059( )mV versus 0.277 +/- 0.046( )mV, p < 0.05) and inhibited the upregulated serum level of creatine kinase (754 +/- 114( )U/l versus 1,112 +/- 239( )U/l, p < 0.05), creatine kinase -MB (700 +/- 95( )U/l versus 1,012 +/- 252( )U/l, p < 0.05) and lactate dehydrogenase (1,174 +/- 200( )U/l versus 2,025 +/- 975( )U/l, p < 0.05) in myocardial ischemia, revealing its cardioprotective effect. It increased a potent tissue protective polypeptide, transforming growth factor beta(1) (TGF-beta(1)) level as well as its receptors TbetaRI and TbetaRII(p < 0.05) and significantly inhibited the expression of a redox-sensitive transcription factor, nuclear factor kappa B (NF-kappaB).
CONCLUSIONS: These data demonstrated that TFFC at the dose of 200 mg/kg body weight exerts prophylactically cardioprotective effect during ischemia injury. Part of its cardioprotective mechanism may relate to induction of TGF-beta(1) to competitively inhibit NF-kappaB signaling pathway. Prophylactically exogenous administration with the component may serve as a novel therapeutic strategy for ischemic cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17674171     DOI: 10.1007/s10557-007-6042-2

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  2 in total

1.  The cardioprotective effects of citric Acid and L-malic Acid on myocardial ischemia/reperfusion injury.

Authors:  Xilan Tang; Jianxun Liu; Wei Dong; Peng Li; Lei Li; Chengren Lin; Yongqiu Zheng; Jincai Hou; Dan Li
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-14       Impact factor: 2.629

2.  The Role of Th17 in Neuroimmune Disorders: A Target for CAM Therapy. Part III.

Authors:  Aristo Vojdani; Jama Lambert; Gottfried Kellermann
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-16       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.